Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
Alliance Appoints New Members to Board of Directors
Each of the four appointees to the Alliance's Board brings unique professional expertise and a personal commitment to the organization's mission to end colorectal cancer in our lifetime.
Bottoms Up® Invitational Raises $5.7 Million in Five Years To Foster a Future Free From CRC
The fifth annual Bottoms Up® Invitational, organized by Today Show anchor Craig Melvin and CBS Sports HQ host Lindsay Czarniak, gathered a passionate crowd of celebrities, musicians, athletes and supporters to raise awareness and funds in the battle against colorectal cancer.
Alliance Launches Online Hub Demystifying Unexpected Home Delivery of Screening Tests
The Colorectal Cancer Alliance and Abbott have launched a new online hub to explain why people receive unexpected home delivery of colorectal cancer screening tests.